Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis
- PMID: 12587953
- DOI: 10.1007/BF03192334
Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis
Abstract
The aim of the study was to compare the feasibility of the MEGX (monoethylglycinexylidide) and antipyrine tests in reference to standard biochemical parameters used for liver assessment in cirrhotic patients. The study was carried out in 44 subjects: 14 healthy controls and 30 cirrhotic patients classified according to the Child-Pugh's score to subgroups A (n=11), B (n=12) and C (n=7). All subjects underwent two dynamic liver tests, i.e. MEGX (monoethylglycinexylidide) and antipyrine test in a crossover schedule with at least 5-day interval. For the MEGX, lidocaine was administrated intravenously, at a dose of 1 mg/kg, and blood samples for MEGX assay were collected after 15 minutes. MEGX concentrations were measured by fluorescence polarization immunoassay. The antipyrine concentrations were evaluated following a single oral administration of 1000 mg antipyrine. The blood was sampled for 24 hours after the drug administration, and antipyrine concentrations were measured spectrophotometrically. Standard biochemical parameters used for liver assessment were measured by means of routine laboratory methods. It was concluded that in patients liver with cirrhosis, liver dynamic tests were better predictors of hepatic function. The MEGX test was more feasible in clinical setting, but it was noted that antipyrine test was more sensitive in staging liver cirrhosis.
Similar articles
-
[Monoethylglycinexylidide--a metabolite of lidocaine--as an index of liver function in chronic hepatic parenchymal diseases].Bratisl Lek Listy. 1999 Jan;100(1):12-24. Bratisl Lek Listy. 1999. PMID: 10492993 Slovak.
-
Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease.Am J Gastroenterol. 1997 Dec;92(12):2268-73. Am J Gastroenterol. 1997. PMID: 9399768
-
Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis.J Hepatol. 1993 Aug;19(1):140-7. doi: 10.1016/s0168-8278(05)80187-4. J Hepatol. 1993. PMID: 8301034 Clinical Trial.
-
[Monoethylglycinexylidide (MEGX)-test. A test for the assessment of prognosis before and after liver transplantation].Dtsch Med Wochenschr. 1995 Feb 10;120(6):179-83. doi: 10.1055/s-2008-1055331. Dtsch Med Wochenschr. 1995. PMID: 7851289 Review. German. No abstract available.
-
The MEGX test: a tool for the real-time assessment of hepatic function.Ther Drug Monit. 2001 Apr;23(2):81-92. doi: 10.1097/00007691-200104000-00001. Ther Drug Monit. 2001. PMID: 11294522 Review.
Cited by
-
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.Aliment Pharmacol Ther. 2009 Mar 1;29(5):589-601. doi: 10.1111/j.1365-2036.2008.03908.x. Epub 2008 Dec 1. Aliment Pharmacol Ther. 2009. PMID: 19053983 Free PMC article. Clinical Trial.
-
Lidocaine clearance as pharmacokinetic parameter of metabolic hepatic activity in patients with impaired liver.J Med Biochem. 2023 Mar 15;42(2):304-310. doi: 10.5937/jomb0-38952. J Med Biochem. 2023. PMID: 36987422 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical